Clinical Trial Search

Phase 3 N=467 Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection

Primary: Percent Change From Baseline in LDL-C at Week 24 — 1.68; -55.23 percent change — p=< 0.0001

Amgen Results Jul 2020 4.4% serious AE View details

Phase 3 N=476 A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Actinic Keratosis

Primary: Percentage of Patients With 100% Clearance of All AK Lesions Within the Treatment Area Assessed at Day 90 — 31; 32; 7; 108 Participants — p=0.0010

Actavis Inc. Results Jul 2020 2.8% serious AE View details

Phase 3 N=403 A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

Alcohol Dependence

Primary: Number of Participants With Adverse Events — 96; 67; 141 Number of participants

Otsuka Pharmaceutical Co., Ltd. Results Jul 2020 0.7% serious AE View details

Phase 3 N=22 Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

SMA - Spinal Muscular Atrophy · Gene Therapy

Primary: Achievement of Independent Sitting for at Least 30 Seconds — 13 Participants — p=<0.0001

Novartis Gene Therapies Results Jul 2020 45.5% serious AE View details

Phase 3 N=853 Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

Epilepsy

Primary: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 84.4 Percentage of participants

UCB Pharma Results Jul 2020 29.1% serious AE View details

Phase 3 N=103 Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

Epilepsy

Primary: Percentage of Participants With at Least One Adverse Event Reported Spontaneously by the Participant/or Caregiver (Including Parent/Legal Guardian) or Observed by the…

UCB BIOSCIENCES, Inc. Results Jul 2020 0.0% serious AE View details

Phase 3 N=440 RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Peripheral Artery Disease · Atherosclerosis · Artery Diseases, Peripheral

Primary: Number of Participants With Primary Lesion Patency — 194; 57; 43 Participants — p=0.0017

Boston Scientific Corporation Results Jul 2020 72.3% serious AE View details

Phase 3 N=158 Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Heterozygous Familial Hypercholesterolemia

Primary: Percent Change From Baseline to Week 24 in LDL-C — -6.23; -44.53 percent change — p=< 0.0001

Amgen Results Jul 2020 0.6% serious AE View details

Phase 3 N=85 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

Infantile Refsum's Disease · Zellweger Syndrome · Adrenoleukodystrophy

Primary: Number of Participants With Excretion of Atypical Bile Acids in Urine by Category — 10; 51; 11; 9 Participants

Mirum Pharmaceuticals, Inc. Results Jul 2020 25.3% serious AE View details

Phase 3 N=383 Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

Hepatocellular Carcinoma

Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…

Daiichi Sankyo Results Jul 2020 47.4% serious AE View details

Phase 3 N=506 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Relapsing Remitting Multiple Sclerosis

Primary: Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B…

Biogen Results Jul 2020 1.4% serious AE View details

Phase 3 N=702 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

BRAF V600E-mutant Metastatic Colorectal Cancer

Primary: (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs) — 5 Participants

Pfizer Results Jul 2020 46.3% serious AE View details

Phase 3 N=900 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

Healthy Volunteers

Primary: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30 — 97.1; 9.1; 98.7 percentage of participants

Takeda Results Jul 2020 1.9% serious AE View details

Phase 3 N=111 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Leukemia, Acute Lymphoblastic

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Amgen Results Jul 2020 36.8% serious AE View details

Phase 3 N=486 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

Primary: Change From Baseline in Number of Binge Days — -2.92; -3.21; -3.47 binge days/week — p=0.1187

Sumitomo Pharma America, Inc. Results Jul 2020 1.0% serious AE View details